FDA approves Roctavian: The U.S. Food and Drug Administration (FDA) has given its stamp of approval to Roctavian, an innovative gene therapy treatment for adults suffering from severe hemophilia A without pre-existing antibodies to the adeno-associated virus serotype 5. Hemophilia A is a rare genetic bleeding disorder predominantly affecting males, brought on by a mutation in the gene responsible for producing factor VIII (FVIII), a … Continue reading FDA approves Roctavian for Gene Therapy for Hemophilia A